SAM
DNLI icon

Shell Asset Management’s Denali Therapeutics DNLI Stock Holding History

Shell Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$22K Sell
1,492
-2,517
-63% -$36.2K ﹤0.01% 1023
2025
Q2 		$56K Sell
4,009
-447
-10% -$6.29K ﹤0.01% 1126
2025
Q1 		$61K Buy
+4,456
New +$85.4K ﹤0.01% 1109

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Shell Asset Management's DNLI Position: Q3 2025 in Review

Shell Asset Management reduced its Denali Therapeutics (DNLI) stake by 63% in Q3 2025, selling an estimated $36.2K and leaving 1,492 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1023.

Shell Asset Management first reported a position in DNLI in Q1 2025 and has held it in 3 quarters since. The position peaked at $61K in Q1 2025. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Shell Asset Management held 1,492 shares of Denali Therapeutics worth $22K as of Q3 2025.
  • Shell Asset Management sold 2,517 Denali Therapeutics shares in Q3 2025, an estimated $36.2K.
  • Denali Therapeutics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1023 holding.
  • Shell Asset Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Shell Asset Management's Denali Therapeutics position peaked at $61K in Q1 2025.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.